Studies of Sulfonylurea Receptors and KATP Channels
磺酰脲受体和KATP通道的研究
基本信息
- 批准号:7015572
- 负责人:
- 金额:$ 32.22万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1994
- 资助国家:美国
- 起止时间:1994-09-20 至 2007-02-28
- 项目状态:已结题
- 来源:
- 关键词:adenosine triphosphateaminoaciddrug receptorselectrophysiologyexpression cloningfluorescence resonance energy transferimmunoprecipitationintermolecular interactionnucleotidespeptide librarypotassium channelprotein localizationprotein protein interactionprotein quantitation /detectionprotein sequenceprotein structure functionsite directed mutagenesissulfonylurea
项目摘要
DESCRIPTION (provided by applicant): The long-term goal of this program is understanding the basis for regulation of ATP-sensitive potassium KATP channels by nucleotides and pharmacologic agents. KATP channels couple membrane electrical activity to cellular energy metabolism and are key regulators in physiologic processes ranging from control of glucose stimulated insulin release to maintenance of vascular smooth muscle tone. Loss of beta-cell KATP channels is a cause of congenital hyperinsulinism, while sulfonylureas like tolbutamide and glibenclamide, are a mainstay in the treatment of NIDDM. Sulfonylurea receptors, SURs, associate with and regulate the pore forming KIR subunits of KATP channels. Past work has established the stoichiometry of KATP channels, (KIR6.x/SUR)4, and identified SUR domains which specify channel isoform differences including those critical for the action of channel blockers and openers. Without SURs, homomeric KIR6.2 pores have a low open channel probability, POmax, are insensitive to sulfonylureas, display altered bursting, are poorly inhibited by ATP, and not stimulated by MgADP, all properties reversed by co-assembly with an SUR. Recent work demonstrates that the first set of transmembrane helices, TMD0, and a connecting segment of SUR, L0, and the amino terminus of KIR6.x, are critical for the control of slow gating. These segments affinity-label with analogues of glibenclamide arguing for their close proximity. The SUR domain critical for SUR-KIR assembly has been identified. TMD0 interacts with KIRS increasing their Pomax while L0 modulates gating in a bi-directional manner. The goal of the proposed research is to define the inter- and intramolecular interactions involved in the assembly and regulation of KATP channels. We have three specific aims: (1) To define the minimal segment of TMD0 needed to interact with KIR6.2 and determine if this is sufficient to activate (KIR6.2deltaC)4 pores. (2) To test the hypothesis that the amino terminus of KIR6.x interacts with the L0 linker of SURs to control bursting. (3) To define further the sulfonylurea/glibenclamide binding pocket of SUR1, specifically to identify amino acids in proximity to the meglitinide head group.
描述(由申请人提供):本项目的长期目标是了解核苷酸和药理学试剂调节ATP敏感性钾KATP通道的基础。KATP通道将膜电活动与细胞能量代谢偶联,并且是从控制葡萄糖刺激的胰岛素释放到维持血管平滑肌张力的生理过程中的关键调节剂。β细胞KATP通道的丧失是先天性高胰岛素血症的原因,而甲苯磺丁脲和格列本脲等磺酰脲类药物是治疗NIDDM的主要药物。磺酰脲受体(SURs)与KATP通道的孔形成KIR亚基结合并调节KIR亚基。过去的工作已经建立了KATP通道的化学计量(KIR6.x/SUR)4,并确定了SUR结构域,其指定通道亚型差异,包括通道阻滞剂和开放剂作用的关键。在没有SUR的情况下,同聚体KIR 6.2孔具有低的开放通道概率POmax,对磺酰脲类不敏感,显示出改变的破裂,受ATP的抑制很差,并且不受MgADP的刺激,所有性质都通过与SUR的共组装而逆转。最近的工作表明,第一套跨膜螺旋,TMD 0,和连接段的SUR,L0,和氨基末端的KIR6.x,是控制慢门控的关键。这些片段与格列本脲类似物具有亲和标记,这说明它们非常接近。已经确定了对SUR-KIR组装至关重要的SUR结构域。TMD 0与KIRS相互作用,增加它们的Pomax,而L0以双向方式调节门控。拟议的研究的目标是确定在组装和调节KATP通道所涉及的分子间和分子内的相互作用。我们有三个具体目标:(1)确定与KIR6.2相互作用所需的TMD 0的最小片段,并确定这是否足以激活(KIR6.2 δ C)4孔。(2)检验KIR6.x的氨基末端与SUR的L0接头相互作用以控制爆发的假设。(3)进一步定义SUR 1的磺酰脲类/格列本脲结合口袋,特别是鉴别靠近美格列奈头部基团的氨基酸。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joseph Bryan其他文献
Joseph Bryan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joseph Bryan', 18)}}的其他基金
Challenging the Dominant Model for ATP Regulation of KATP Channels
挑战 KATP 通道 ATP 调节的主导模型
- 批准号:
8994733 - 财政年份:2014
- 资助金额:
$ 32.22万 - 项目类别:
Challenging the Dominant Model for ATP Regulation of KATP Channels
挑战 KATP 通道 ATP 调节的主导模型
- 批准号:
8788349 - 财政年份:2014
- 资助金额:
$ 32.22万 - 项目类别:
Challenging the dominant model for ATP regulation of KATP channels
挑战 KATP 通道 ATP 调节的主导模型
- 批准号:
8630333 - 财政年份:2014
- 资助金额:
$ 32.22万 - 项目类别:
Challenging the Dominant Model for ATP Regulation of KATP Channels
挑战 KATP 通道 ATP 调节的主导模型
- 批准号:
9199412 - 财政年份:2014
- 资助金额:
$ 32.22万 - 项目类别:
TRANSGENIC MOUSE MODEL FOR FAMILIAL HYPERINSULINISM
家族性高胰岛素血症转基因小鼠模型
- 批准号:
6381037 - 财政年份:1998
- 资助金额:
$ 32.22万 - 项目类别:
TRANSGENIC MOUSE MODEL FOR FAMILIAL HYPERINSULINISM
家族性高胰岛素血症转基因小鼠模型
- 批准号:
2905823 - 财政年份:1998
- 资助金额:
$ 32.22万 - 项目类别:
TRANSGENIC MOUSE MODEL FOR FAMILIAL HYPERINSULINISM
家族性高胰岛素血症转基因小鼠模型
- 批准号:
6358711 - 财政年份:1998
- 资助金额:
$ 32.22万 - 项目类别:
相似海外基金
Asymmetric Single-Chain MspA nanopores for electroosmotic stretching and sequencing proteins
用于电渗拉伸和蛋白质测序的不对称单链 MspA 纳米孔
- 批准号:
10646810 - 财政年份:2023
- 资助金额:
$ 32.22万 - 项目类别:
Exploring the Role of Nitrogen Metabolism in Cancer
探索氮代谢在癌症中的作用
- 批准号:
10737792 - 财政年份:2023
- 资助金额:
$ 32.22万 - 项目类别:
Discovery of neoepitope immunotherapeutic targets in diffuse pediatric high-grade gliomas
弥漫性儿童高级别胶质瘤中新表位免疫治疗靶点的发现
- 批准号:
10774404 - 财政年份:2023
- 资助金额:
$ 32.22万 - 项目类别:
Structurally engineered N-acyl amino acids for the treatment of NASH
用于治疗 NASH 的结构工程 N-酰基氨基酸
- 批准号:
10761044 - 财政年份:2023
- 资助金额:
$ 32.22万 - 项目类别:
Detecting cell to cell contacts in zebrafish with a synthetic receptor methodology
使用合成受体方法检测斑马鱼的细胞与细胞接触
- 批准号:
10645331 - 财政年份:2023
- 资助金额:
$ 32.22万 - 项目类别:
A novel peptide assay for hepcidin clinical monitoring
一种用于铁调素临床监测的新型肽测定方法
- 批准号:
10698746 - 财政年份:2023
- 资助金额:
$ 32.22万 - 项目类别:
New approach based on enzyme stimulating of peptides for targeting drug resistance breast cancers
基于肽酶刺激的新方法用于靶向耐药性乳腺癌
- 批准号:
10713648 - 财政年份:2023
- 资助金额:
$ 32.22万 - 项目类别:
Rusalatide Acetate (TP508) Mitigation Effect on Radiation Induced Keratopathy
醋酸鲁沙来肽 (TP508) 对放射诱发的角膜病变的缓解作用
- 批准号:
10605739 - 财政年份:2023
- 资助金额:
$ 32.22万 - 项目类别:
Identifying the Molecular Function of the Y-linked Mouse Zinc Finger Proteins ZFY1 and ZFY2
鉴定 Y 连锁小鼠锌指蛋白 ZFY1 和 ZFY2 的分子功能
- 批准号:
10749409 - 财政年份:2023
- 资助金额:
$ 32.22万 - 项目类别:
Discovery and Roles of In Situ Islet Neoantigens in Human Type 1 Diabetes
原位胰岛新抗原在人类 1 型糖尿病中的发现及其作用
- 批准号:
10589578 - 财政年份:2023
- 资助金额:
$ 32.22万 - 项目类别: